Aspiriant LLC Has $2.35 Million Stock Holdings in Abbott Laboratories $ABT

Aspiriant LLC cut its stake in Abbott Laboratories (NYSE:ABT) by 10.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,259 shares of the healthcare product maker’s stock after selling 2,001 shares during the period. Aspiriant LLC’s holdings in Abbott Laboratories were worth $2,347,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Hoese & Co LLP raised its holdings in Abbott Laboratories by 444.4% in the 2nd quarter. Hoese & Co LLP now owns 2,450 shares of the healthcare product maker’s stock valued at $333,000 after acquiring an additional 2,000 shares in the last quarter. Foster & Motley Inc. raised its holdings in shares of Abbott Laboratories by 10.7% during the 2nd quarter. Foster & Motley Inc. now owns 4,506 shares of the healthcare product maker’s stock worth $613,000 after buying an additional 435 shares in the last quarter. Huntleigh Advisors Inc. raised its holdings in shares of Abbott Laboratories by 21.7% during the 2nd quarter. Huntleigh Advisors Inc. now owns 20,454 shares of the healthcare product maker’s stock worth $2,782,000 after buying an additional 3,644 shares in the last quarter. Chevy Chase Trust Holdings LLC raised its holdings in shares of Abbott Laboratories by 1.0% during the 2nd quarter. Chevy Chase Trust Holdings LLC now owns 949,801 shares of the healthcare product maker’s stock worth $129,182,000 after buying an additional 9,062 shares in the last quarter. Finally, Stratos Wealth Partners LTD. raised its holdings in shares of Abbott Laboratories by 1.4% during the 2nd quarter. Stratos Wealth Partners LTD. now owns 109,462 shares of the healthcare product maker’s stock worth $14,888,000 after buying an additional 1,551 shares in the last quarter. 75.18% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.46% of the company’s stock.

Analyst Ratings Changes

ABT has been the subject of a number of research analyst reports. Wells Fargo & Company boosted their price target on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a report on Thursday. Weiss Ratings reissued a “buy (b)” rating on shares of Abbott Laboratories in a report on Wednesday, October 8th. Jefferies Financial Group boosted their price target on Abbott Laboratories from $145.00 to $149.00 and gave the stock a “buy” rating in a report on Thursday. Mizuho boosted their price target on Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday. Finally, BTIG Research restated a “buy” rating and set a $145.00 price objective on shares of Abbott Laboratories in a research report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $147.61.

Abbott Laboratories Trading Up 0.8%

Shares of ABT stock opened at $128.69 on Friday. The firm has a market capitalization of $223.98 billion, a P/E ratio of 16.13, a P/E/G ratio of 2.42 and a beta of 0.69. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. The stock’s fifty day simple moving average is $132.38 and its 200 day simple moving average is $131.54.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.30. Abbott Laboratories had a return on equity of 17.78% and a net margin of 31.88%.The business had revenue of $11.37 billion for the quarter, compared to analyst estimates of $11.40 billion. During the same quarter in the previous year, the company posted $1.21 EPS. Abbott Laboratories’s quarterly revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. This represents a $2.36 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Wednesday, October 15th. Abbott Laboratories’s payout ratio is 29.57%.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.